Related Experiment Videos
Five-year Irish trial of CLI patients with TASC II type C/D lesions undergoing subintimal angioplasty or bypass
1Western Vascular Institute, Department of Vascular & Endovascular Surgery, University College Hospital, and The Galway Clinic, Galway, Ireland. mrsherif.sultan@gmail.com
Insights
Subintimal angioplasty (SIA) offers improved outcomes for critical limb ischemia (CLI) patients compared to bypass grafting (BG). SIA demonstrated reduced major adverse events and costs, enhancing quality-adjusted life years.
Area of Science:
- Vascular Surgery
- Interventional Cardiology
- Health Economics
Background:
- Critical limb ischemia (CLI) significantly impacts patient quality of life and limb salvage rates.
- TASC II type C/D lesions in lower limb arteries present complex challenges for revascularization.
- Subintimal angioplasty (SIA) and bypass grafting (BG) are established treatment options for CLI.
Purpose of the Study:
- To compare the 5-year effectiveness of SIA versus BG for treating TASC II type C/D lower limb arterial lesions in CLI patients.
- To evaluate secondary endpoints including major adverse events (MAE), restenosis, target lesion revascularization (TLR), and quality-adjusted life years (QALY).
- To conduct a cost analysis comparing SIA and BG treatments.
Main Methods:
- A 5-year observational parallel group study involving 190 patients undergoing SIA and 119 patients undergoing BG.
- Patients presented with Rutherford classification 4-6 ischemia (rest pain and/or tissue loss).
- Primary endpoints included survival free from amputation and sustained clinical improvement; secondary endpoints covered MAE, restenosis, TLR, Q-TWiST, and cost-effectiveness.
Main Results:
- At 5 years, sustained clinical improvement was higher in the SIA group (82.8%) vs. BG group (68.2%).
- All-cause survival and amputation-free survival were similar between groups.
- SIA significantly reduced MAE (p<0.002) and hospital stay (p<0.0001), with improved Q-TWiST (p<0.001) and lower cost-per-QALY (p<0.002).
Conclusions:
- SIA demonstrated a 20% enhanced 5-year freedom from MAE compared to BG.
- SIA offers substantial cost reductions and improved quality-adjusted life years (Q-TWiST).
- SIA represents a minimally invasive approach that enhances amputation-free and symptom-free survival, potentially shifting CLI management paradigms.
Purpose:
To report a 5-year observational parallel group study comparing the effectiveness of subintimal angioplasty (SIA) to bypass grafting (BG) for treatment of TASC II type C/D lesions in the lower limb arteries of patients with critical limb ischemia (CLI).
Methods:
Of 1076 patients referred with PVD from 2002 to 2007, 206 SIAs in 190 patients (104 women; mean age 73+/-13 years) and 128 bypass grafts in 119 patients (77 men; mean age 70+/-14 years) were enrolled in the study. All patients had Rutherford classification 4-6 ischemia manifested as rest pain and/or tissue loss. Primary endpoints were (1) survival free from amputation and (2) sustained clinical improvement [+2 Rutherford category and/or ABI increase >0.15 without target lesion revascularization (TLR)]. Secondary endpoints were major adverse events (MAE), the binary restenosis rate, freedom from TLR, and a special quality-adjusted life year (QALY) endpoint (Q-TWiST) that incorporated both length and quality of life to evaluate treatments. A cost analysis was also performed.
Results:
At 5 years, clinical improvement was sustained in 82.8% of the SIA group versus 68.2% of the BG patients (p = 0.106). Five-year all-cause survival was similar for SIA (78.6%) and BG (80.1%; p = 0.734), as was amputation-free survival (SIA 72.9% versus BG 71.2%; p = 0.976). Hyperfibrinogenemia (p = 0.009) and C-reactive protein (p = 0.019) had negative effects on survival without amputation. Five-year freedom from binary restenosis rates were 72.8% for SIA versus 65.3% for BG (p = 0.700). While the 5-year freedom from TLR rates (SIA 85.9% versus BS 72.1%, p = 0.262) were not statistically significant, the risk of MAE (p<0.002) and length of hospital stay (p<0.0001) were significantly reduced in the SIA group. Q-TWiST significantly improved (p<0.001) and cost-per-QALY (SIA euro5663 versus BG euro9172, p<0.002) was reduced with SIA. The 5-year risk of re-intervention (p>0.05) and mean number of procedures (p = 0.078) were similar.
Conclusion:
Five-year freedom from MAE was enhanced by 20% in the SIA group, with substantial cost reduction and better Q-TWiST. SIA is a minimally invasive technique that expands amputation-free and symptom-free survival. SIA is poised to bring about a paradigm shift in the management of CLI.
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Peripheral Artery Disease III: Interprofessional Care
Aneurysm III: Interprofessional Care
Transient Ischemic Attack l: Introduction